Skip to content

Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2

Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04174313
Acronym
VILIVORTEX
Enrollment
65
Registered
2019-11-22
Start date
2020-03-10
Completion date
2021-06-09
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Mechanical Ventilation Complication, Ventilator-Induced Lung Injury

Brief summary

The concept of Ventilator-induced Lung Injury Vortex (VILI vortex) has recently been proposed as a progressive lung injury mechanism in which the alveolar stress/strain increases as the ventilable lung shrinks (1). This positive feedback inexorably leads to the acceleration of lung damage, with potentially irreversible results. Little is known about the clinical aspects of this condition. Understanding its behavior could contribute to changing its potential devastating impact. The objective of this study is to evaluate the incidence of VILI vortex in patients with acute respiratory syndrome (ARDS) secondary to COVID-19, to establish a connection between this phenomenon and mortality, and to identify the factors that have an impact on its development.

Detailed description

Mechanical ventilation is an essential tool for the treatment of patients with acute respiratory distress syndrome (ARDS). However, as with other strategies, it is not free of complications. Inadequate ventilation may have a negative impact on pulmonary and systemic hemodynamics, and it could both cause structural damage to pulmonary parenchyma and activate inflammation (2). This process is known as ventilator-induced lung injury (VILI) and may promote the development of multiple organ failure and, eventually, death. VILI results from the interaction between the mechanical load applied to the ventilable lung and its capacity to tolerate it. Factors such as tidal volume (Vt), driving pressure (ΔP), inspiratory flow rate (VI), respiratory rate (RR), excessive inspiratory effort, high levels of FiO2 and, in some cases, PEEP, have been involved in damage mechanism. In that sense, the concept of mechanical power (MP) tries to encompass most of these factors within a measurable unit (3). Furthermore, the decrease in ventilable lung volume (baby lung concept), the heterogeneous lung compromise in ARDS), and the presence of cofactors that have a negative impact on the lung (fluid overload, presence of sepsis or shock) could increase its susceptibility to damage (4-5). Due to the fact that the mechanical conditions of the lung change dynamically with the progression of the disease, the ventilatory strategy needs constant adjustments in order to maintain a balance between the load and the size of the ventilable lung (concept of ergonomic ventilation). In fact, a protective ventilatory strategy of low tidal volume (Vt: 6 ml/kg/PBW) and limited plateau pressure (PPlat \<30 cmH2O) may cause damage if the functional residual capacity (FRC) decreases significantly, thus making a lower number of alveoli (including capillaries) withstand a higher mechanical load per unit. The concept of VILI vortex has recently been proposed as a progressive lung injury mechanism in which the alveolar stress/strain increases as the ventilable lung shrinks. This positive feedback inexorably leads to the acceleration of lung damage, with potentially irreversible results (1). Little is known about the clinical aspects of this condition. Understanding its behavior could contribute to changing its potential devastating impact. The objective of this study is to evaluate the incidence of VILI vortex in patients with ARDS secondary to COVID-19, to establish a connection between this phenomenon and mortality, and to identify the factors that have an impact on its development.

Interventions

DIAGNOSTIC_TESTCT scan

Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions. Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased. Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning.

Sponsors

Hospital El Cruce
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

ARDS \-

Exclusion criteria

Patients with do-not-resuscitate (DNR) orders and pregnant women. Cardiac arrest before ICU admission. Extra corporeal membrane oxygenation (ECMO) requirement within the first 24 h of ICU admission and chronic obstructive pulmonary disease with gold class 3 or 4, or home oxygen therapy

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Who Survived and Died90 daysThe number of patients who died and survived was compared between patients with SARS-CoV-2 who progressed with VILI VORTEX and without VILI VORTEX)
Number of Patients With and Without Refractory Hypoxemia90 daysThe number of patients that evolved with refractory hypoxemia was compared between the patients with SARS-CoV-2 that evolved with VILI VORTEX and without VILI VORTEX) Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning.
Number of Patients With Complications90 daysThe following variables and complications were also observed during the period of analysis: incidence of pneumonia associated with mechanical ventilation, need for noradrenaline over 0.1 γ/kg/min for more than 24 h, positive blood cultures, accumulated fluid balance, dialysis treatment, clinical and/or echocardiographic evidence of heart failure, lactate ≥2 mmol/L in at least two consecutive samples, presence of persistent fever (≥38º at least once a day for three consecutive days), and the highest value of ferritin, D-dimer, C-reactive protein, troponin I and LDH obtained during the first 14 days of invasive mechanical ventilation. VILI vortex patients had positive blood cultures, moderate to severe shock, persistent fever and fluid balance was considerably more positive.

Countries

Argentina

Participant flow

Recruitment details

Patients were recruited between March 2020 to March 2021

Pre-assignment details

No patients with SARS-CoV-2 were excluded from the study prior to group assignment.

Participants by arm

ArmCount
VILI VORTEX
Participants who evolved with VILI vortex clinical criteria
15
No VILI VORTEX
Participants who evolved without clinical criteria for VILI vortex
50
Total65

Baseline characteristics

CharacteristicVILI VORTEXNo VILI VORTEXTotal
Age, Continuous59 years60 years60 years
Comorbidities
Cancer/immunosupresion
4 participants6 participants10 participants
Comorbidities
COPD
3 participants7 participants10 participants
Comorbidities
Diabetes Mellitus
25 participants33 participants58 participants
Comorbidities
Hypertension
9 participants25 participants34 participants
Comorbidities
Ischemic heart disease
2 participants6 participants8 participants
Comorbidities
Obesity
5 participants11 participants16 participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
15 Participants50 Participants65 Participants
Region of Enrollment
Argentina
15 participants50 participants65 participants
Sex: Female, Male
Percentage of male and female patients
Female
6 Participants18 Participants24 Participants
Sex: Female, Male
Percentage of male and female patients
Male
9 Participants32 Participants41 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
14 / 1519 / 50
other
Total, other adverse events
10 / 1520 / 50
serious
Total, serious adverse events
14 / 1523 / 50

Outcome results

Primary

Number of Participants Who Survived and Died

The number of patients who died and survived was compared between patients with SARS-CoV-2 who progressed with VILI VORTEX and without VILI VORTEX)

Time frame: 90 days

Population: The evolution of the patients was compared with Chi square, significant p \<0.05

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
VILI VORTEXNumber of Participants Who Survived and DiedSurvivors1 Participants
VILI VORTEXNumber of Participants Who Survived and DiedDead14 Participants
No VILI VORTEXNumber of Participants Who Survived and DiedSurvivors31 Participants
No VILI VORTEXNumber of Participants Who Survived and DiedDead19 Participants
Primary

Number of Patients With and Without Refractory Hypoxemia

The number of patients that evolved with refractory hypoxemia was compared between the patients with SARS-CoV-2 that evolved with VILI VORTEX and without VILI VORTEX) Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning.

Time frame: 90 days

Population: The baseline characteristics of the population were similar for both groups.

ArmMeasureGroupValue (NUMBER)
VILI VORTEXNumber of Patients With and Without Refractory Hypoxemiawith refractory hypoxemia1 participants
VILI VORTEXNumber of Patients With and Without Refractory Hypoxemiano refractory hypoxemia49 participants
No VILI VORTEXNumber of Patients With and Without Refractory Hypoxemiawith refractory hypoxemia14 participants
No VILI VORTEXNumber of Patients With and Without Refractory Hypoxemiano refractory hypoxemia1 participants
Primary

Number of Patients With Complications

The following variables and complications were also observed during the period of analysis: incidence of pneumonia associated with mechanical ventilation, need for noradrenaline over 0.1 γ/kg/min for more than 24 h, positive blood cultures, accumulated fluid balance, dialysis treatment, clinical and/or echocardiographic evidence of heart failure, lactate ≥2 mmol/L in at least two consecutive samples, presence of persistent fever (≥38º at least once a day for three consecutive days), and the highest value of ferritin, D-dimer, C-reactive protein, troponin I and LDH obtained during the first 14 days of invasive mechanical ventilation. VILI vortex patients had positive blood cultures, moderate to severe shock, persistent fever and fluid balance was considerably more positive.

Time frame: 90 days

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
VILI VORTEXNumber of Patients With ComplicationsRenal replacement therapy7 Participants
VILI VORTEXNumber of Patients With ComplicationsBood cultures9 Participants
VILI VORTEXNumber of Patients With ComplicationsPersistent fever7 Participants
VILI VORTEXNumber of Patients With Complicationsintranosocomial pneumonia7 Participants
No VILI VORTEXNumber of Patients With ComplicationsPersistent fever10 Participants
No VILI VORTEXNumber of Patients With ComplicationsRenal replacement therapy18 Participants
No VILI VORTEXNumber of Patients With Complicationsintranosocomial pneumonia19 Participants
No VILI VORTEXNumber of Patients With ComplicationsBood cultures10 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026